PI
-
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results
Corre, J., Vincent, L., Moreau, P., Hebraud, B., Hulin, C., Béné, M.-C., Broijl, A., Caillot, D., Delforge, M., Dejoie, T., Facon, T., Lambert, J. R., Leleu, X., Macro, M., Perrot, A., Zweegman, S., Filleron, T., Cabarrou, B., van de Donk, N. W. C. J. & Mahéo, S. & 11 others, , 7 Aug 2025, In: Blood. 146, 6, p. 679-692 14 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
Korst, C. L. B. M., Tahri, S., Duetz, C., Bruins, W. S. C., de Jonge, A. V., de Jong, M. E., Fokkema, C., Smits, F., Groen, K., Verkleij, C. P. M., Frerichs, K. A., Papazian, N., van Duin, M., van Beek, G., Hoogenboezem, R., Baardemans, T., Dal Collo, G., Stoetman, E. C. G., Cosovic, M. & Twickler, I. & 15 others, , 19 Jun 2025, In: Blood. 145, 25, p. 3007-3014 8 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
High immunoproteasome and low constitutive proteasome subunit levels correlate with sensitivity to bortezomib-containing chemotherapy: update from the Children’s Oncology Group AALL1231 trial
Roeten, M. S. F., van Meerloo, J., van Dijk, S. N., Kwidama, Z., Jenkins, G., Teachey, D. T., Devidas, M., Loh, M. L., Kaspers, G. J. L., Zweegman, S., Jansen, G., Horton, T. M. & Cloos, J., 1 Jun 2025, In: Haematologica. 110, 6, p. 1379-1383 5 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
- All publications